Initiates Coverage on InVivo Therapeutics (NASDAQ:NVIV)

Equities researchers at assumed coverage on shares of InVivo Therapeutics (NASDAQ:NVIVGet Rating) in a research report issued on Sunday. The brokerage set a “sell” rating on the biotechnology company’s stock.

InVivo Therapeutics Trading Down 1.9 %

Shares of NASDAQ:NVIV opened at $4.93 on Friday. The company has a fifty day simple moving average of $5.84 and a 200 day simple moving average of $5.85. The firm has a market cap of $6.85 million, a PE ratio of -0.64 and a beta of 1.05. InVivo Therapeutics has a 12-month low of $3.50 and a 12-month high of $17.71.

Institutional Trading of InVivo Therapeutics

An institutional investor recently raised its position in InVivo Therapeutics stock. Renaissance Technologies LLC raised its holdings in shares of InVivo Therapeutics Holdings Corp. (NASDAQ:NVIVGet Rating) by 152.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 79,300 shares of the biotechnology company’s stock after purchasing an additional 47,900 shares during the period. Renaissance Technologies LLC owned about 5.78% of InVivo Therapeutics worth $27,000 as of its most recent SEC filing. 4.53% of the stock is currently owned by institutional investors.

InVivo Therapeutics Company Profile

(Get Rating)

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI.

Read More

Receive News & Ratings for InVivo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVivo Therapeutics and related companies with's FREE daily email newsletter.